Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 04-Jul-2022 08:32:00

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Primary Care Networks

Action category: Action

Title: Commencement of a Palivizumab Passive Immunisation Programme Against Respiratory Syncytial Virus (RSV) in At Risk Infants in England, Scotland and Wales

Broadcast content:

Following an observed sustained rise in rates of respiratory syncytial virus (RSV) infection, acute trusts / health boards in England, Scotland and Wales are asked to immediately offer a programme of monthly doses of palivizumab, administered as a intramuscular injection, for a period of up to 7 months to provide protection against respiratory syncytial virus (RSV) for at risk infants as defined in the green book

Alert reference: CEM/CMO/2022/011


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency